Pancreatic Cancer Research

ResearcherKeio UniversityActive in the last 2 years

Minoru Kitago

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4909-1199; OpenAlex author ID A5014273795. Sources: OpenAlex.

Their work

Papers
47 (first author 18, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
152
Papers, trials and grants by year

2014: 3 papers · 2015: 3 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 3 papers · 2021: 5 papers · 2022: 1 paper · 2023: 3 papers · 2024: 8 papers · 2025: 9 papers · 2026: 5 papers

Papers 47

  1. Impact of Sarcopenia During Induction Treatment in Patients With Unresectable Locally Advanced Pancreatic Cancer. Co-author DOI 10.1002/ags3.70078↗
  2. Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02343-2↗
  3. Postoperative risk stratification after upfront surgery for resectable pancreatic ductal adenocarcinoma in the S-1 adjuvant era. Co-author DOI 10.1016/j.pan.2026.05.008↗
  4. Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Co-author DOI 10.1038/s41416-025-03308-7↗
  5. A Pancreatic Ductal Adenocarcinoma Diagnostic System Using Serum Extracellular Vesicle Detection with Optimized Lectin Combination Using Machine Learning. Co-author DOI 10.3390/cancers18060924↗
  6. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  7. Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate. Co-author DOI 10.1158/1078-0432.ccr-25-2333↗
  8. Clinical Impact of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Single-Center Retrospective Study. First author DOI 10.1245/s10434-024-16851-z↗
  9. ASO Author Reflections: Indication Criteria for Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-025-16980-z↗
  10. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
  11. Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Cancer (TOSPAC-02): A Phase 2 Clinical Tria… Co-author DOI 10.1245/s10434-025-17661-7↗
  12. ASO Author Reflections: Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Cancer (TOSPAC-02)-… Co-author DOI 10.1245/s10434-025-17876-8↗
  13. Pancreatic Cancer in Hereditary Breast and Ovarian Cancer Syndrome: Is Early Detection Possible? First author DOI 10.2302/kjm.2024-0018-oa↗
  14. Pancreatic Cancer Mimicking Relapse of Autoimmune Pancreatitis: Case Reports. First author DOI 10.70352/scrj.cr.25-0076↗
  15. Adjuvant 5-fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer. Co-author DOI 10.1002/cam4.7459↗
  16. Wnt-deficient and hypoxic environment orchestrates squamous reprogramming of human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41556-024-01498-5↗
  17. Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-72569-8↗
  18. Prognosis prediction of PDAC via detection of O-glycan altered extracellular vesicles in perioperative sera. Co-author DOI 10.1111/cas.16341↗
  19. Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study. First author DOI 10.1186/s12957-024-03609-w↗
  20. Efficacy and safety of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer First author DOI 10.21203/rs.3.rs-4671932/v1↗
  21. Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review. First author DOI 10.3390/cancers16091632↗
  22. Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid. Co-author DOI 10.3892/ol.2024.14272↗
  23. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗
  24. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  25. Long-term survival after surgical resection for bone metastasis from pancreatic cancer: A case report. First author DOI 10.1097/md.0000000000035856↗
  26. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  27. Clinicopathological impacts of DNA methylation alterations on pancreatic ductal adenocarcinoma: prediction of early recurrence based on genome-wide DNA methyla… Co-author DOI 10.1007/s00432-021-03541-6↗
  28. Hereditary pancreatic cancer. First author DOI 10.1007/s10147-021-02015-6↗
  29. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen. Co-author DOI 10.1158/1078-0432.ccr-20-2298↗
  30. Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report. Co-author DOI 10.1186/s13053-020-00160-z↗
  31. Peritoneal dissemination of pancreatic cancer caused by endoscopic ultrasound-guided fine needle aspiration: A case report and literature review. First author DOI 10.3748/wjg.v27.i3.294↗
  32. Usefulness of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant thera… First author DOI 10.1002/cam4.3044↗
  33. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. First author DOI 10.1111/cas.14425↗
  34. O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. Co-author DOI 10.3390/cancers12092469↗
  35. Characterization of spatial distribution of tumor-infiltrating CD8+ T cells refines their prognostic utility for pancreatic cancer survival. Co-author DOI 10.1038/s41379-019-0291-z↗
  36. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline rese… First author DOI 10.1186/s12957-019-1687-4↗
  37. Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma. First author DOI 10.3892/mco.2019.1883↗
  38. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. First author DOI 10.1038/bjc.2017.479↗
  39. Mesenchymal-epithelial transition of pancreatic cancer cells at perineural invasion sites is induced by Schwann cells. Co-author DOI 10.1111/pin.12641↗
  40. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. First author DOI 10.1002/cam4.1178↗
  41. Two cases of pancreatic ductal adenocarcinoma with intrapancreatic metastasis. First author DOI 10.3748/wjg.v22.i41.9222↗
  42. Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/labinvest.2014.166↗
  43. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. First author DOI 10.1111/cas.12621↗
  44. Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer. Co-author DOI 10.2302/kjm.2014-0014-cr↗
  45. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Soc… Co-author DOI 10.1002/jhbp.15↗
  46. Computer assisted surgery, preoperative planning and navigation for pancreatic cancer. Co-author DOI 10.1002/jhbp.84↗
  47. Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/labinvest.2014.53↗

Closest collaborators

The 25 strongest of 152 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuko Kitagawa · 31 shared papers, 2014–2026 · strength 4.83
  2. Yuta Abe · 24 shared papers, 2014–2026 · strength 3.65
  3. Yutaka Nakano · 20 shared papers, 2017–2026 · strength 3.30
  4. Shutaro Hori · 17 shared papers, 2019–2026 · strength 3.01
  5. Yohei Masugi · 23 shared papers, 2014–2026 · strength 3.00
  6. Masayuki Tanaka · 11 shared papers, 2021–2026 · strength 2.28
  7. Yutaka Endo · 12 shared papers, 2018–2025 · strength 2.01
  8. Sho Uemura · 9 shared papers, 2022–2026 · strength 1.81
  9. Gaku Shimane · 7 shared papers, 2023–2026 · strength 1.60
  10. Yuko Kitagawa · 6 shared papers, 2024–2025 · strength 1.20
  11. Michiie Sakamoto · 11 shared papers, 2014–2023 · strength 0.90
  12. Yosuke Uematsu · 4 shared papers, 2025–2026 · strength 0.86
  13. Koichi Aiura · 7 shared papers, 2015–2025 · strength 0.82
  14. Kodai Abe · 4 shared papers, 2020–2025 · strength 0.65
  15. Yosuke Inoue · 4 shared papers, 2022–2026 · strength 0.63
  16. Kiyoshi Hasegawa · 4 shared papers, 2022–2026 · strength 0.63
  17. Manabu Takamatsu · 4 shared papers, 2022–2026 · strength 0.63
  18. Tsuyoshi Takeda · 4 shared papers, 2022–2026 · strength 0.63
  19. Tatsunori Suzuki · 4 shared papers, 2022–2026 · strength 0.63
  20. Tsuyoshi Hamada · 4 shared papers, 2022–2026 · strength 0.63
  21. Yu Takahashi · 4 shared papers, 2022–2026 · strength 0.63
  22. Yousuke Nakai · 4 shared papers, 2022–2026 · strength 0.63
  23. Mitsuhiro Fujishiro · 4 shared papers, 2022–2026 · strength 0.63
  24. Naoki Sasahira · 4 shared papers, 2022–2026 · strength 0.63
  25. Eisuke Iwasaki · 3 shared papers, 2021–2025 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.